In the NeoPHOEBE phase II trial, buparlisib was evaluated in the neoadjuvant setting: patients with HER2+ early BC, regardless of PIK3CA mutation, were randomized to receive trastuzumab plus either buparlisib or placebo for six weeks, followed by trastuzumab and paclitaxel plus buparlisib or placebo. The gene discussed is PIK3CA; the disease is breast cancer.